Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.

Abstract

AIM Sorafenib is the standard of care in advanced hepatocellular carcinoma. This study was aimed to identify clinical parameters that may predict survival in these patients. MATERIALS & METHODS In this observational study, a training (226 patients) and validation cohorts (54 patients) were analyzed for evaluating pretreatment and on-treatment parameters… (More)
DOI: 10.2217/fon.14.291

6 Figures and Tables

Topics

  • Presentations referencing similar topics